Oramed; First patient enrolled in study of oral insulin capsule for NASH - Hallo friendsTHE LEK NEWS, In the article you read this time with the title Oramed; First patient enrolled in study of oral insulin capsule for NASH, We have prepared this article for you to read and retrieve information therein. Hopefully the contents of postings Article culture, Article economy, Article health, Article healthy tips, Article news, Article politics, Article sports, We write this you can understand. Alright, good read.

Title : Oramed; First patient enrolled in study of oral insulin capsule for NASH
link : Oramed; First patient enrolled in study of oral insulin capsule for NASH

Oramed; First patient enrolled in study of oral insulin capsule for NASH

Oramed Enrolls First Patient in Its Clinical Study for Oral Insulin in the Treatment of NASH

NEW YORK, Oct. 4, 2018 /PRNewswire/ — Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today it has enrolled the first patient in an exploratory clinical study of its oral insulin capsule, ORMD-0801, in the treatment of nonalcoholic steatohepatitis (NASH).

The three-month treatment study, recently approved by Israel’s Ministry of Health, will assess the effectiveness of ORMD-0801 in reducing liver fat content, inflammation and fibrosis in patients with NASH.

Data from preclinical studies and clinical studies of ORMD-0801 demonstrate Oramed’s oral insulin capsule has the potential to reduce inflammation of the liver.

“Prevalence of NASH is accelerating rapidly and correlates directly with the rising incidence of type 2 diabetes. As we continue our focus on the development of our oral insulin for the treatment of diabetes, we are excited about its potential in this greatly needed NASH indication,” stated Oramed CEO, Nadav Kidron.

NASH, a chronic liver disease caused by excessive fat in the liver, can lead to fibrosis, cirrhosis, liver failure and death. According to the Journal of Hepatology, prevalent NASH cases are expected to increase 63% from 16 million in 2015 to 27 million cases in 2030.

About Oramed Pharmaceuticals 

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, Oramed’s Protein Oral Delivery (PODTM) technology is based on over 30 years of research by top scientists at Jerusalem’sHadassah Medical Center. Oramed is seeking to revolutionize the treatment of diabetes through its proprietary flagship product, an orally ingestible insulin capsule (ORMD-0801). The Company completed multiple Phase II clinical trials under an Investigational New Drug application with the U.S. Food and Drug Administration. In addition, Oramed is developing an oral GLP-1 analog capsule (ORMD-0901).

https://www.oramed.com/oramed-enrolls-first-patient-in-its-clinical-study-for-oral-insulin-in-the-treatment-of-nash/

Thus Article Oramed; First patient enrolled in study of oral insulin capsule for NASH

That's an article Oramed; First patient enrolled in study of oral insulin capsule for NASH This time, hopefully can give benefits to all of you. well, see you in posting other articles.

You are now reading the article Oramed; First patient enrolled in study of oral insulin capsule for NASH with the link address https://theleknews.blogspot.com/2018/10/oramed-first-patient-enrolled-in-study.html

Tweet

Subscribe to receive free email updates: